What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
Translating targeted therapy from bench to bedside has been more problematic in SLE than other autoimmune diseases, with many theoretically well-founded agents appearing to have failed in clinical trials as a result of inefficacy, problem with trial design and/or safety issues.
David Liew drdavidliew
3 years 6 months ago
Treat-to-target in RA is held with an almost religious fervour in rheumatology, but it's really hard to follow religiously. What happens if you're only T2T observant on the high holidays?
Answer: the world's not too bad!
(2y is bit short I realise)
POS0111 #EULAR2022 @RheumNow https://t.co/Boh74JmsP3
Dr. John Cush RheumNow
3 years 6 months ago
Watch: Treatment of Pre-RA: Is Early Already Too Late?
Dr. Aurelie Najm reviews abstract OP0070 presented at the #EULAR2022 meeting. #MedEd
https://t.co/ep4lgtZYcT https://t.co/LTx1RMGdkv
Eric Dein ericdeinmd
3 years 6 months ago
#EULAR2022 OP0067:
Depression is a major risk factor (6X!) for mortality in RA. Study may show some bias in the methods, but critical findings for all rheumatologists to consider
@RheumNow
https://t.co/leeY9zAx4T
Dr. Antoni Chan synovialjoints
3 years 6 months ago
Updates in Psoriatic Arthritis at EULAR 2022. Here are the topics I will be highlighting at the conference #psoriaticarthritis #EULAR2022 @RheumNow https://t.co/8Dd29GdUuz
TheDaoIndex KDAO2011
3 years 6 months ago
“Evidence does not support a risk of flares in association with any vaccination.” – Dr. Kimme Hyrich https://t.co/z179YYn9mc
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 6 months ago
In a rush for a quick update on selected trial results in #lupus presented at #EULAR2022? Please find my article https://t.co/0XTkPRr6kQ @RheumNow
Dr. Rachel Tate uptoTate
3 years 6 months ago
To contrast or not to contrast (in RA hand MRI?) POS0718 from #EULAR2022 showed good correlation between contrast/non-contrast imaging in synovitis, less so in tenosynovitis however. https://t.co/xL4XcRlIog
@RheumNow https://t.co/0cTep6MHLu
Dr. John Cush RheumNow
3 years 6 months ago
WATCH: Can Dermatologists Help Detect Psoriatic Arthritis?
Dr. Robert Chao reviews abstract OP0029 presented at #EULAR2022 in June.
https://t.co/bAuCsVLJV2 https://t.co/BjUckSXIJ3
Symplur Hashtags healthhashtags
3 years 6 months ago
Top Influencers of #EULAR2022: @eular_org @RichardPAConway @RheumNow @EMEUNET @rheum_cat @Yuz6Yusof More 📊 https://t.co/fUfohEZAoX
Poster Hall